The Oklahoma Shared Clinical and Translational Resources

The OSCTR is funded by the National Institutes of Health as part of its IDeA-CTR program. We have the mission to serve as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Clinical and Translational Science Institute

 

OCTSI is the home of the OSCTR, as well as clinical research services and dissemination and implementation resources to help improve the delivery of healthcare. 

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

Subscribe to News

Recent Publications

Mapping Long COVID: Spatial and Social Inequities Across the United States

medRxiv [Preprint]. 2025 Aug 26:2025.08.21.25334183. doi: 10.1101/2025.08.21.25334183.

ABSTRACT

BACKGROUND: Long COVID affects a substantial portion of the U.S. population, yet its spatiotemporal distribution remains poorly characterized. The emergence of the Omicron variant and persistent sociodemographic disparities may contribute to regional variation in long COVID risk. Understanding the patterns of long COVID is essential to implementing targeted and equitable public health interventions.

Impact of Preexisting Rare Diseases on COVID-19 Severity, Reinfection, and Long COVID, and the Modifying Effects of Vaccination and Antiviral Therapy: A Retrospective Study from the N3C Data Enclave

medRxiv [Preprint]. 2025 Jul 10:2025.07.09.25331138. doi: 10.1101/2025.07.09.25331138.

ABSTRACT

BACKGROUND: Over 10,000 rare diseases (RDs) affect more than 300 million people globally, yet their influence on COVID-19 severity, reinfection risk, and long COVID remains poorly understood. This study evaluates the impact of RDs on these outcomes and examines the effectiveness of vaccination and antiviral treatments among individuals with and without RDs.

Upcoming Events

Media